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Abstract 
Background: The production of recombinant proteins containing disulfide bonds in Escherichia coli is challenging. In 
most cases the protein of interest needs to be either targeted to the oxidizing periplasm or expressed in the cyto‑
plasm in the form of inclusion bodies, then solubilized and re‑folded in vitro. Both of these approaches have limita‑
tions. Previously we showed that soluble expression of disulfide bonded proteins in the cytoplasm of E. coli is possible 
at shake flask scale with a system, known as CyDisCo, which is based on co‑expression of a protein of interest along 
with a sulfhydryl oxidase and a disulfide bond isomerase. With CyDisCo it is possible to produce disulfide bonded 
proteins in the presence of intact reducing pathways in the cytoplasm.
Results: Here we scaled up production of four disulfide bonded proteins to stirred tank bioreactors and achieved 
high cell densities and protein yields in glucose fed‑batch fermentations, using an E. coli strain (BW25113) with the 
cytoplasmic reducing pathways intact. Even without process optimization production of purified human single chain 
 IgA1 antibody fragment reached 139 mg/L and hen avidin 71 mg/L, while purified yields of human growth hormone 
1 and interleukin 6 were around 1 g/L. Preliminary results show that human growth hormone 1 was also efficiently 
produced in fermentations of W3110 strain and when glucose was replaced with glycerol as the carbon source.
Conclusions: Our results show for the first time that efficient production of high yields of soluble disulfide bonded 
proteins in the cytoplasm of E. coli with the reducing pathways intact is feasible to scale‑up to bioreactor cultivations 
on chemically defined minimal media.
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Background
The production of recombinant proteins in Escheri-
chia coli has a number of advantages over other sys-
tems including fast growth, well characterized genetics, 
high productivity and an organism that is Generally 
Recognized As Safe (GRAS). However, expression of 
homogenously folded proteins containing post-trans-
lational modifications such as disulfide bonds is chal-
lenging. Disulfide bonds are covalent linkages that are 
essential for the native structure and biological activ-
ity of many secreted and outer membrane proteins [1]. 
In natural systems disulfide bonds are synthesized in 
cellular compartments that are able to maintain an oxi-
dizing environment e.g. the endoplasmic reticulum in 
eukaryotes and the periplasm of Gram-negative bac-
teria. In most cellular compartments, disulfide bonds 
are synthesized de novo by a sulfhydryl oxidase that 
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oxidizes cysteine thiols; additionally, proteins with mul-
tiple disulfide bonds need a disulfide bond isomerase that 
rearranges randomly oxidized disulfides to their native 
configuration [2]. In contrast, the cytoplasm contains 
multiple pathways for the reduction of disulfide bonds 
and these are crucial for catalytic turnover of cytoplasmic 
enzymes such as ribonucleotide reductase [3].
The most common way to deal with such difficult-to-
express proteins in E. coli on an industrial scale is either 
to target the protein to the periplasm or to synthesize the 
protein of interest (POI) as inclusion bodies in the cyto-
plasm and subsequently solubilize and refold in vitro [4].
Escherichia coli hosts enzymes that catalyze disulfide 
bond formation in the periplasm, therefore a recombi-
nant protein can be targeted to and potentially fold in 
this compartment. However, the periplasm constitutes 
only 8 to 16% of the total bacterial cell volume [5]; more-
over, heterologous proteins need a signal sequence on the 
N-terminus to be exported to the periplasm and there is 
only a limited number of transporters that allow proteins 
to cross the cytoplasmic membrane and they can easily 
become overloaded [6]. These two factors combine to 
result in typically low protein yields upon periplasmic 
expression unless extensive optimization of production 
processes is undertaken.
In contrast, the cytoplasm of E. coli has a high capac-
ity for accumulating recombinant proteins, which can 
exceed 30% of the total cellular protein [4]. Therefore, 
many marketed pharmaceuticals produced in E. coli are 
produced as inclusion bodies [7, 8]. Inclusion bodies 
are formed when a protein emerging from the ribosome 
is unfolded or misfolded and hence are likely to aggre-
gate. Although inclusion bodies can be produced in high 
yields, are easily physically separated from other cellular 
components and are resistant to cellular proteases [8], 
their use is problematic as elaborate in  vitro solubiliza-
tion, refolding and purification procedures are required 
to recover biologically active protein. Furthermore, 
refolding conditions need to be optimized for each POI 
and in many cases only 15–25% of inclusion bodies will 
be converted to bioactive product [9]. In addition, sepa-
ration of correctly folded from partially folded POI can 
be very problematic as they can have very similar bio-
physical properties.
Although several strategies have been developed to 
promote biosynthesis of soluble proteins in the cyto-
plasm of E. coli, including expression at lower tem-
peratures (15–23  °C), co-expression of molecular 
chaperones, protein engineering and attachment of 
fusion tags, modification of growth media [8], they are 
very often inefficient for production of proteins with 
disulfide bonds and/or are infeasible for larger scale 
production [10]. Engineering attempts to create strains 
specifically dedicated for cytoplasmic expression of pro-
teins containing disulfide bonds have been based on the 
disruption of genes of reducing cytoplasmic enzymes 
[11]. In commercially available strains, such as Ori-
gami (Novagen) and SHuffle (New England Biolabs), the 
thioredoxin reductase (trxB) and glutathione reductase 
(gor) genes are deleted. The SHuffle strain additionally 
expresses the bacterial disulfide bond isomerase DsbC 
in the cytoplasm. However the viability of these strains 
relies on another mutation located in peroxiredoxin 
aphC gene that suppresses redox deficiencies [12]. The 
yield of recombinant disulfide-bonded proteins obtained 
in redox engineered strains is usually low and still often 
requires assistance of molecular chaperones [13] or 
extensive optimization of growth conditions e.g. tem-
perature, rich media, time and strength of induction, 
etc. [14]. Although engineered strains are well marketed, 
there is no evidence of their efficient soluble protein 
productivity at bioreactor scale in chemically defined 
minimal media since they require the addition of yeast 
extract and soytone [15].
The issues in both periplasmic and cytoplasmic expres-
sion of disulfide bond containing proteins suggests a 
need for an alternative system for large scale production 
in E. coli, in particular one which will allow production in 
chemically defined minimal media.
Based on the mechanisms for natural disulfide bond 
formation in other cellular compartments we have 
developed a system called CyDisCo (cytoplasmic 
disulfide bond formation in E. coli), in which solu-
ble expression of a recombinant protein containing 
disulfide bonds in the cytoplasm of E. coli is possible 
thanks to pre-expression or co-expression of a sulfhy-
dryl oxidase (usually Erv1p from Saccharomyces cere-
visiae) and a disulfide bond isomerase (usually human 
PDI [16, 17]). While ΔtrxB/Δgor strains cannot be 
grown in chemically defined minimal media, probably 
due to the role of the reducing pathways in processes 
such as DNA synthesis through catalytic turnover of 
ribonucleotide reductase [3], the CyDisCo system does 
not require disruption of the reducing pathways and 
hence it should in theory be possible to use it in chemi-
cally defined minimal media. In addition the CyDisCo 
system is easily transferred between expression hosts 
[16–19].
In this work we undertook proof of concept studies to 
see if it is possible to produce disulfide bond containing 
proteins in chemically defined minimal media using the 
CyDisCo system. We tested expression in fed-batch fer-
mentation of three human proteins, whose native struc-
ture is stabilized by disulfide bonds: growth hormone 1 
(GH1), interleukin 6 (IL-6) and a single chain variable 
fragment (scFv), as well as chicken avidin.
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Results
CyDisCo has previously been shown to allow efficient 
cytoplasmic production of a range of disulfide bond con-
taining proteins, including GH1, interleukins and anti-
body fragments such as scFv, in both deep well plates 
and shake flasks [16–19]. Unlike ΔtrxB/Δgor strains such 
as Origami CyDisCo has no requirement to disrupt the 
reducing pathways in the cytoplasm and this should 
allow growth in defined minimal media. We therefore 
hypothesized that CyDisCo should be amenable to large 
scale cultivation e.g. in fed-batch fermentation. Here we 
tested that hypothesis with fermentation scale growth of 
two proteins which have previously been shown to work 
in shake flask scale (human GH1 [19] and an  IgA1 based 
scFv [17]) as well as human IL-6 and chicken avidin.
CyDisCo has a number of formats. Those that involve 
the use of transmembrane catalysts i.e. inverted VKOR 
or inverted DsbB [20] require more optimization as too 
high level of over-expression of the transmembrane com-
ponent is deleterious to the host while too little results 
in inefficient disulfide bond formation. In contrast the 
CyDisCo variants based on Erv1p are well tolerated.
Here CyDisCo has been applied in either a one- or 
two-plasmid based format. GH1, IL-6 and avidin were 
expressed from a one-plasmid based format, specifically 
a polycistronic modified pET23-based vector with a Ptac 
promoter that carries also genes for parallel synthesis of 
Erv1p (Saccharomyces cerevisiae) and PDI (human). scFv 
 IgA1 was expressed using a two-plasmid format with the 
scFv expressed from a pET23-based plasmid with a Ptac 
promoter, while CyDisCo components i.e. Erv1p and PDI 
are co-expressed from the second, pLysS-based vector, 
under a Ptac promoter and with a p15A origin of replica-
tion. Both CyDisCo formats are functional in fed-batch 
fermentation on minimal defined media (see below).
Initial proof of concept cultivations were performed 
in 1 L stirred tank reactors in fed-batch cultures grown 
on minimal defined media with glucose as the carbon 
source. Protein production was induced during expo-
nential growth phase. The cultures achieved good cell 
densities, with cell dry weight (CDW) up to 28.5  g/L, 
indicating that cell growth is not impaired by the expres-
sion of CyDisCo components. Higher cell densities could 
potentially be reached in an optimized process.
Initial experiments focused on GH1 production in fed-
batch fermentation in E. coli strain BW25113 (parental 
strain of the KEIO collection). Since Erv1p uses molecu-
lar oxygen, dissolved oxygen level was maintained at 30% 
of air saturation as is standard for E. coli fermentations 
rather than the low dissolved oxygen levels required for 
ΔtrxB/Δgor strains [15]. Since Erv1p does not tolerate 
37 °C well, cultures were either grown at 30 °C (Fig. 1a) or 
grown initially at 37 °C to accumulate biomass, then the 
temperature was decreased to 30  °C for protein induc-
tion (Fig.  1b). Both methods produced soluble GH1 in 
high yields. The GH1 produced was purified by Immobi-
lized Metal Affinity Chromatography (IMAC) followed 
by buffer exchange using a PD-10 gel filtration column 
to remove low molecular weight species which might 
absorb at 280 nm (Fig. 1c, d). The variability in purified 
protein yield between purifications from a single fermen-
tation (9%) was comparable with the variability between 
fermentations (12%) indicating that the use of CyDisCo 
on fermentation scale is reproducible and robust. The 
yield of purified GH1 obtained was 0.97 ± 0.12 g/L (aver-
age 39 mg/g CDW).
GH1 purified from fermentation showed the expected 
molecular weight (Table 1) for the protein with disulfides 
present after treatment with N-ethylmaleimide, while 
an Ellman’s assay indicated 0.09 free thiol groups per 
protein. rpHPLC analysis of GH1 produced in fermen-
tation showed a single species for GH1 and an identical 
profile to that produced in shake flask cultures (Fig. 1e). 
The presence of the correct number of disulfides, a sin-
gle species by rpHPLC and high yields (implying protease 
resistance) indicates that CyDisCo can efficiently pro-
duce GH1 with native disulfide bonds in the cytoplasm of 
E.coli in fed-batch fermentation. To our knowledge this is 
the first evidence that disulfide bond containing proteins 
can be produced efficiently in the cytoplasm of E. coli in 
chemically defined minimal media.
The use of ΔtrxB/Δgor strains not only requires the use 
of complex additives e.g. yeast extract, they also put limi-
tations on the strain used. In contrast, CyDisCo can be 
freely transferred between strains and has worked in all 
B- and K-strains tested to date. Preliminary data indicates 
that this extends to fermentation scale growth (Addi-
tional file  1: Figure S1; strain W3110, yield of purified 
GH1 0.28 g/L; 18 mg/g CDW). In addition, preliminary 
data indicates that glycerol can be used in place of glu-
cose as the carbon source with no loss of efficient pro-
duction (Additional file  1: Figure S1; strain BW25113 
yield of purified GH1 0.75  g/L; 37  mg/g CDW c.f. an 
average of 39 mg/g CDW with growth on glucose).
To ensure that the results obtained were not protein 
specific i.e. that CyDisCo has wider application in fed 
batch fermentation, the expression of other proteins 
was tested. Preliminary results with other proteins pro-
duced as per GH1, indicates that similar high yields can 
be obtained for IL-6 (Additional file 1: Figure S2, yield of 
purified IL-6 1.1 g/L; 41 mg/g CDW) while lower yields 
were obtained for chicken avidin (Additional file 1: Figure 
S3, yield of purified avidin 71 mg/L; 3.6 mg/g CDW).
The starting point for fermentation of a protein of 
interest i.e. prior to protein specific optimization varies 
considerably between research groups.
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As proof of concept of the wider applicability of 
CyDisCo an alternative and very different methodol-
ogy set for fermentation was used for scFv  IgA1. scFv 
 IgA1 producing fermentations were grown at 30  °C and 
a constant feeding rate was applied (Fig. 2a). After induc-
tion about half of the scFv was produced in a soluble 
form in the cytoplasm of E. coli and a purified yield of 
139 ±  10  mg/L (average 6.6  mg/g CDW) was obtained 
(Fig.  2b). scFv  IgA1 purified from fermentation showed 
the expected molecular weight (Table 1) for the protein 
with disulfides present, while an Ellman’s assay indicated 
0.03 free thiol groups per protein. Preliminary results 
with other scFv (data not shown) indicate scFv-depend-
ent yields up to 0.6  g/L, similar to the scFv-dependent 
yields seen in smaller scale cultures [16]. This possibly 
arises due to the difference in solubility of the scFv with 
Fig. 1 Production of GH1. a, b Representative growth profiles of K‑12 strain BW25113 co‑expressing coPDI, coErv1p and GH1; a constant tempera‑
ture growth, b growth at 37 °C to increase cell mass, then shift to 30 °C pre‑induction. Error bars represent the standard deviation from 3 samples. F 
indicates feeding started, I indicates induction. Cells were harvested and protein purified from the last time point shown. c Representative elution 
profile from IMAC purification of GH1. d Coomassie stained reducing SDS‑PAGE analysis of produced proteins: molecular marker, total E. coli lysate 
(T), soluble protein fraction (S) and IMAC purified GH1. e rpHPLC analysis of purified GH1: comparison of GH1 produced in fed‑batch fermentation 
(red) and in shake flask (black)
Table 1 Analysis of free thiols content in purified proteins based on mass spectrometry and Ellman’s assay
The molecular weight of the purified proteins was determined after treatment with N-ethylmaleimide, which reacts with free thiol groups and adds 125 Da. Expected 
molecular weight assumes all cysteines are present as disulfides. No N-ethylmaleimide adducts were observed implying all cysteines were in disulfide bonds. The free 
thiol content of the purified proteins was determined by Ellman’s assay under denaturing conditions
N/D not determined
Protein Number of Cys Expected mw (Da) Experimental mw (Da) Free thiols per molecule
GH1 4 23,210 23,211 0.09
IL‑6 4 21,894 21,894 −0.01
ScFv  IgA1 4 27,342 27,342 0.03
Avidin 2 15,426 15,426 N/D
Page 5 of 12Gąciarz et al. Microb Cell Fact  (2017) 16:108 
scFv solubilities being highly variable due to the comple-
mentary determining regions (CDRs).
Upstream and downstream processing places stress on 
the cells and any system used on an industrial scale needs 
to be robust. To examine the robustness of cells contain-
ing the CyDisco system Bradford analysis of sheared vs 
non-sheared cells harvested after 32  h of fermentation 
of cultures expressing scFv  IgA1 was used. The results 
showed no difference in total soluble protein released 
from the cells (Fig.  2c). These data indicate that the E. 
coli strains with CyDisCo are robust and not sensitive to 
shearing forces normally generated during upstream and 
downstream processing.
Discussion
Escherichia coli is a first-choice host for recombinant 
protein production, however the production of proteins 
with disulfide bonds is limited in this host. The cytoplasm 
of E. coli is a reducing environment hence the forma-
tion of disulfide bonds is favored only in the periplasm, a 
compartment which can be problematic for the efficient 
production of recombinant proteins. When a heterolo-
gous protein is expressed in the cytoplasm of E. coli the 
unfavorable folding environment can lead to aggregation 
and formation of insoluble inclusion bodies. Although 
inclusion bodies can be solubilized and re-folded in vitro, 
the procedures often require extensive and expensive 
protein specific optimization. In addition, the final yield 
of natively folded active protein can be low and the sepa-
ration of natively folded and misfolded or partially folded 
protein can be problematic since their biophysical prop-
erties e.g. isoelectric point are often very similar. In addi-
tion, methods that are developed in research facilities on 
the shake flask scale are often infeasible on larger scale.
While systems based on disruption of the cytoplasmic 
pathways for disulfide reduction have been reported and 
marketed for the production of disulfide bond containing 
proteins, these strains require the use of complex addi-
tives e.g. yeast extract and/or soytone.
Previously we showed that E. coli strains express-
ing CyDisCo components along with a protein of inter-
est allow efficient disulfide bond formation and protein 
folding to native state for proteins including alkaline 
phosphatase, AppA [16], GH1 [19], BPTI, vtPA, resistin, 
Ero1α, CFS3, BMP4, catalytic light chain of enterokinase, 
IFNα2, IL-17 [18] and multiple scFv and Fab antibody 
fragments [17]. The yields of protein obtained reported 
could be up to 800-fold higher than in the absence of 
CyDisCo [18]. We also revealed that disruption of the 
reducing pathways in the cytoplasm is not necessary for 
soluble production of disulfide bonded proteins [16]. 
However, all published research is based on cultures cul-
tivated on rich media, such as LB or EnPressoB, and all 
grown in deep well plates or in shake flasks. Such small 
scale cultivations may be sufficient for protein produc-
tion for academic research, but are not apt for industrial 
scale. Growth conditions in shake flasks are difficult to 
measure and cannot be easily controlled and hence large 
batch-to-batch variations may occur. In contrast, pro-
duction in bioreactors allows key variables such as pH, 
temperature, dissolved oxygen level and nutrient sup-
ply to be regulated. Chemically defined minimal media 
is preferred for large scale of protein production since it 
provides full control over media composition, avoiding a 
lot-to-lot variability of undefined components, it there-
fore assures reproducibility of the process and the qual-
ity of the final product. In addition, it is free of animal 
derived components. The slower growth profile of the 
Fig. 2 Production of scFv  IgA1. a Representative growth profile of K‑12 strain BW25113 co‑expressing coPDI, coErv1p and scFv  IgA1. Error bars 
represent the standard deviation from 3 samples. F indicates feeding started, I indicates induction. Cells were harvested and protein purified from 
the last time point shown. b Coomassie stained reducing SDS‑PAGE analysis of produced proteins: molecular marker, total E. coli lysate (T), soluble 
protein fraction (S) and IMAC purified scFv. c Bradford analysis of sheared (+) and non‑sheared (−) cells from two fermentations of scFv  IgA1 (n = 6). 
There was no significant difference in protein concentration between sheared and non‑sheared cells indicating the E. coli strains with CyDisCo 
components are robust
Page 6 of 12Gąciarz et al. Microb Cell Fact  (2017) 16:108 
cells on defined minimal media may be beneficial for pro-
tein folding, while it still allows implementation of fed-
batch cultivations yielding high cell densities [21]. In the 
present research we scaled up cultivations.
Here we show that the limitation of E. coli cytoplasm 
for the production of recombinant disulfide-bonded pro-
teins can be overcome by the introduction of CyDisCo 
components and that this system is feasible for scale-up 
to bioreactor cultures on chemically defined minimal 
media. In the present proof of concept research we scaled 
up cultivations of E. coli cultures producing recombinant 
proteins in presence of CyDisCo components to stirred 
tank bioreactors with expression under standard condi-
tions 30  °C, pH = 7,  pO2 = 30% on chemically defined, 
minimal media and the process was successful. Our 
K-12 (wild-type) strain cultures reached good cell den-
sities and high protein yields: purified GH1 and IL-6 
were around 1 g/L, while purified scFv  IgA1 productivity 
reached 139 mg/L and avidin 71 mg/L, using two differ-
ent standard starting fermentation protocols i.e. without 
protein specific optimization. In the case of the scFv  IgA1 
the glucose concentration was high through the fermen-
tation and that may have repressed protein production. 
Protein and strain specific process optimization is likely 
to both increase the cell densities and protein productiv-
ity. To our knowledge this is the first report showing the 
efficient production of disulfide bond containing proteins 
in the cytoplasm of E.coli in chemically defined minimal 
media and our non-optimized yields of up to 1 g/L sug-
gest it has potential industrial as well as academic use.
Our results contrast with the available data on soluble 
protein production in a bioreactor system in the cyto-
plasm of commercial available ΔtrxB/Δgor strains such as 
SHuffle or Origami. For example, Chung et al. [22] used 
SHuffle strain in fed-batch fermentation with rich media 
for the production of giant grouper growth hormone, 
however the protein was produced only in the form of 
inclusion bodies. Similarly Brüsehaber et al. [23] used the 
Origami strain with rich media for the production of pig 
liver esterase, but no soluble protein was obtained from 
fed-batch fermentation, only from batch fermentations. 
Lamppa et al. [24] were able to employ the SHuffle strain 
in fermentation for production of human lysozyme, how-
ever they managed to obtain soluble lysozyme only after 
co-expression of additional folding chaperones, Skp and 
Trigger factor resulting in the production of 21 mg/L of 
soluble lysozyme, far below the protein production lev-
els reported here. In addition, the standard protocol for 
the use of SHuffle in fermentations [15] indicates that 
the strain requires complex additives (yeast extract and 
soytone), low concentrations of glycerol (below 2%) and 
low dissolved oxygen level (5–10%) in order to grow. 
Under the recommended cultivation conditions for 
fermentation SHuffle strains reach a final  OD600 of only 
25–30. SHuffle strains can be also cultivated on glucose 
as carbon source, but low dissolved oxygen level will 
cause organic acid accumulation and inhibition of growth 
[15].
The results of our study indicate that efficient produc-
tion of valuable proteins such as GH1, IL-6, scFv  IgA1 
and avidin in a soluble folded form in the cytoplasm of 
E. coli is possible in chemically defined minimal media, 
although all of them have a long history of cumber-
some attempts to produce them in active form. Growth 
hormone plays a key role in stimulating growth, repro-
duction and regeneration of cells. Historically it was 
extracted from cadaver pituitaries, but this led to several 
cases of Creutzfeld–Jacob disease, therefore its recom-
binant counterpart was of high interest. It is a non-
glycosylated protein therefore there is a preference for 
production in prokaryotic cells. It was first synthetized 
in E. coli as inclusion bodies by Genentech and recombi-
nant GH1 was accepted by the FDA in 1985 [25]. Today 
there are several GH1 pharmaceuticals produced in 
E. coli available on the market (Nutropin or Protropin 
(Genentech), Norditropin (Novo Nordisk), Genotropin 
(Pharmacia and Upjohn Company), Humatrope (Eli Lilly 
and Company) [26]), however, production is based on 
inclusion body formation, thus multiple methods for sol-
ubilization and re-folding have been developed. In con-
trast, there is no reported E. coli system we are aware of 
for production of IL-6 that would be economically fea-
sible at larger scale. IL-6 is a human cytokine involved 
in a broad range of biological functions, e.g. acts as pro-
inflammatory cytokine and anti-inflammatory myokine; 
it is associated with a number of inflammatory diseases, 
e.g. rheumatoid arthritis, atherosclerosis, diabetes. Its 
mature form has 2 sequential disulfide bonds and one 
N-glycosylation site. IL-6 expressed in E. coli cytoplasm 
as inclusion bodies requires intensive solubilization pro-
tocols [27]. IL-6 solubility in the cytoplasm has been sig-
nificantly increased through fusion with tags e.g. NusA 
[28] and MBP [29]; however, a large proportion of the 
protein is lost during removal of the MBP-tag, result-
ing in a final yield of 270 mg/L [29]. Nausch et al. tested 
several approaches of IL-6 production, the most suc-
cessful method produced 2.6 mg/L of active IL-6 in the 
cytoplasm of E. coli BL21 by co-expression with chaper-
ones DnaK, DnaJ, GrpE, GroES, GroEL and lowering the 
cultivation temperature to 22 °C; authors report that this 
method was more successful than production in Ori-
gami 2 [30]. IL-6 targeted for secretion through hemo-
lysin export apparatus via fusion with  HlyAS secretional 
signal yielded in 18 µg/L of fusion protein [31]. In con-
trast we report here 1.1 g/L of purified IL-6 from non-
optimized fermentation.
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ScFv constitute of an immunoglobulin variable light 
(VL) and variable heavy (VH) domain connected by a 
flexible linker; each domain is stabilized by one disulfide 
bond. ScFv are the smallest antibody fragments retaining 
the antigen binding capacity and specificity, therefore 
have potential applications in research, diagnostic and 
as therapeutic agents. In 2009 there were 19 scFv under 
clinical trials [32]. In comparison to the full length anti-
body scFv can penetrate tumor tissue more efficiently, 
while their clearance from the blood and retention time 
in non-target tissue is shorter. scFv lack the Fc region 
therefore they are less immunogenic than full length 
antibodies and do not require N-glycosylation, making 
them suitable for production in prokaryotic cells. Fv-
fragments had already been produced in the periplasm 
of E. coli in 1988 [33], but prior to CyDisCo only scFv 
that do not require disulfide bonds for correct folding, 
and are thus soluble, were made in the cytoplasm of E. 
coli [34]. Previously using CyDisCo we produced a vari-
ety of scFv on shake flask scale in EnPresso-B media 
[17], where scFv  IgA1 yielded 68  mg/L purified protein 
(7.9 mg/g CDW). Scaling up the production of this pro-
tein to a bioreactor on minimal media here increased the 
yield to 139 mg/L (6.6 mg/g CDW) through an increase 
in cell density.
Avidin is a glycoprotein synthesized in oviducts of 
avians, reptiles and amphibians. Avidin forms a non-
covalent complex with biotin, with the strongest known 
affinity (Kd =  10−15  M) [35], making it useful for many 
research applications, including detection and purifi-
cation of nucleic acids and proteins. However, avidin 
is highly glycosylated and has a high pI of 10–10.5 that 
contributes to nonspecific interactions and lectin bind-
ing. Deglycosylation of avidin decreases the pI to 6.3 and 
reduces lectin binding, thus increasing specificity for bio-
tin without affecting affinity [36]; this form of avidin is 
called neutravidin. On an industrial scale avidin is puri-
fied from chicken egg white, in which it constitutes about 
0.05% of total protein [37] (approximately 1.5–2  mg/
egg). This production method is difficult to scale-up and 
results in batch-to-batch variation. Attempts to pro-
duce avidin in E. coli resulted in yields of 20  mg/L of 
active protein recovered from inclusion bodies [38] or 
10  mg/L of soluble protein from periplasmic produc-
tion [39]. Here we produced soluble aglycosylated avidin 
in the cytoplasm of E. coli on bioreactor scale with puri-
fied yields of 71 mg/L from a non-optimized expression 
system.
Currently expression of recombinant proteins in E. 
coli accounts for 30% of production of marketed phar-
maceuticals [40], with the inability to carry out post-
translational modifications causing it to lose its leading 
role to Chinese Hamster Ovary (CHO) cultures [41]. In 
contrast to bacterial cultures CHO have high nutritional 
requirements, grow slowly, are very fragile and instable; 
establishment and optimization of production strains 
for each protein of interest takes a long time correlating 
with high production costs [41]. Moreover, glycosylation 
patterns are heterogeneous [42] and the downstream 
processing requires the clearance of viruses [43]. Our 
results clearly show that the limitation related to forma-
tion of disulfide bonds in the cytoplasm of E. coli can 
be overcome by introduction of the CyDisCo system 
and that this can be applied in production of disulfide 
bonded proteins on larger scale in chemically defined 
minimal media. Our system can compete with CHO cul-
tures for disulfide formation and has the potential to be 
a cheaper and more efficient method for pharmaceutical 
protein production.
Conclusions
Here we show that E. coli K-12 strains with intact reduc-
ing pathways and co-expressing CyDisCo components 
are feasible to scale-up at bioreactor scale and can be 
applied for biosynthesis of valuable proteins containing 
disulfide bonds on a larger scale in chemically defined 
minimal media. Good cell densities and high yields of sol-
uble protein were achieved using defined minimal media 
in glucose fed-batch cultures, without requiring process 
or strain optimization. Preliminary data suggests that 
CyDisCo can be employed in cultures utilizing glycerol as 
main carbon source as well; moreover, the CyDisCo sys-
tem can be facilely transferred between E. coli strains.
Methods
All chemicals used in this study, unless specified other-
wise, were purchased from Sigma Aldrich and were of 
analytical grade.
Strain and vectors
Two strains were used in this study: the parental 
strain of Keio collection single gene knock outs  K-12 
BW25113 [rrnB3 ΔlacZ4787 hsdR514 Δ(araBAD)567 
Δ(rhaBAD)568 rph-1] [44, 45] and K-12 W3110  [F− 
 lambda− IN(rrnD-rrnE)1 rph-1] [46, 47]. Both strains 
have the cytoplasmic reducing pathways intact.
Expression vectors (Table  2) were made by standard 
molecular biology techniques.
The vector for expression of scFv  IgA1 (pJV84) was a 
modified version of pET23 in which the T7 promoter was 
replaced with the tac promoter (Ptac), as described previ-
ously [17].
A polycistronic expression construct pMJS205 for 
codon optimized Erv1p and codon optimized mature 
PDI was made in modified pLysS vector as described pre-
viously [17].
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pMJS144, pMJS145 and pYU25 are polycistronic vectors 
constructed for co-expression of three proteins: protein 
of interest with hexa-histidine tag on N-terminus, yeast 
sulfhydryl oxidase Erv1p and human protein disulfide 
isomerase (PDI). Genes encoding Erv1p (Saccharomy-
ces cerevisiae Erv1p: Met1-Glu189) and PDI (human 
mature PDI: Asp18-Leu508) were synthesized codon 
optimized (co) for E. coli expression (GenScript). They 
were cloned NdeI/BamHI into a modified pET23d vector 
[48]. The generated vectors (pMJS1 and pMJS2, respec-
tively) were digested with XbaI/NdeI and the short frag-
ments were replaced by annealed oligonucleotide pairs 
S1E1 for coErv1p and S1P1 for coPDI (S1E1f CTAGATT-
TATTATTTGATTCTATAAAGAAGGAGATAT; S1E1r 
TAATATCTCCTTCTTTATAGAATCAAATAATAAAT; 
S1P1f CTAGAATAATAAATCATAAGTAATAAGAA-
GGAGATAT; S1P1r TAATATCTCCTTCTTATTACT-
TATGATTTATTATT) to create vectors pMJS92 and 
pMJS96, respectively. The vector containing coErv1p 
was digested with BamHI/XhoI and the small fragment 
was replaced with annealed oligonucleotide pair S2 (S2f 
GATCTATATGACTAGTATATTAATTGATCATA; S2r 
TCGATATGATCAATTAATATACTAGTCATATA). 
The resulting vector was digested with SpeI/BclI and the 
digested fragment was replaced with XbaI/BamHI frag-
ment from the coPDI containing vector pMJS96. The 
vector now containing coErv1p and coPDI was digested 
XbaI/BglI and the fragment was ligated into a SpeI/BglI 
digested modified pET23 vector containing Ptac instead 
of T7 promoter [17] and additional SpeI restriction site 
inserted after C-terminal His-tag using site directed 
mutagenesis, to generate vector pMJS143. The genes 
encoding for mature GH1 (Phe27–Phe217) and mature 
IL-6 (Val30-Met212) were amplified using IMAGE clones 
(http://www.imageconsortium.org) as templates and 
cloned NdeI/BamHI into pMJS143 to generate pMJS144 
and pMJS145. Gene encoding for mature hen avidin 
(Ala25-Glu152) was cloned NdeI/BamHI from a codon 
optimized GenScript construct into pMJS143 to generate 
pYU25.
All plasmids were purified using the Gen-Elute HP 
Plasmid Miniprep Kit (Sigma Aldrich) and all DNA frag-
ments were purified from agarose gels using the Gel/PCR 
DNA Fragments Extraction Kit (GeneAid), both accord-
ing to the manufacturers’ instructions.
All generated constructs were sequenced to confirm 
that there are no errors in the cloned genes.
Cultivation media
Liquid LB media contained per litre: 10 g NaCl, 10 g tryp-
tone, 5 g yeast extract; additionally 15 g of agar was used 
for preparation of LB-agar plates.
Mineral salt medium (MSM) had the following com-
position (per liter): 2  g  Na2SO4, 2.7  g  (NH4)2SO4, 0.5  g 
 NH4Cl, 14.0  g  KHPO4, 3.6  g  NaH2PO4  ×  H2O, 1.0  g 
 (NH4)2 citrate [49].
After sterilization, the MSM was supplemented with 
sterile solutions of 100  µg/mL thiamine hydrochloride 
and 2  mL/L of trace element solution that included per 
liter: 0.5 g  CaCl2 ×  2H2O, 0.18 g  ZnSO4 ×  7H2O, 0.1 g 
 MnSO4 × H2O, 20.1 g  Na2-EDTA, 16.7 g  FeCl3 × 6H2O, 
0.16 g  CuSO4 × 5H2O, 0.18 g  CoCl2 × 6H2O [50].  MgSO4 
was added to the final concentration of 2 mM at the start 
of the fermentation and again during the fermentation, as 
indicated below.
100  µg/mL of ampicillin and, where required, 35  µg/
mL of chloramphenicol (i.e. for strains co-transformed 
with pMJS205) were used as selection markers in all LB-
agar plates and liquid media, as well as in the feeding 
solutions.
Fermentation cultures expressing GH1, IL‑6 and avidin
Escherichia coli K-12 strains transformed with plasmid 
pMJS144, pMJS145 or pYU25 were stored in 20% glyc-
erol at −70  °C; when needed the strains were streaked 
out from the glycerol stock onto LB-agar plates and incu-
bated overnight at 37 °C. The next day a few colonies were 
used to seed 10 mL of LB media and incubated overnight 
(14 h) at 30 °C, 180 rpm. 1 mL of overnight culture was 
used to inoculate 200  mL of MSM (containing 40  g/L 
glucose), which was then incubated at 37 °C, 160 rpm for 
about 18  h. The MSM-based pre-cultures were applied 
to inoculate the batch of 0.6 L of sterile MSM containing 
10 g/L of glucose or glycerol to a starting  OD600 = 0.5.
For most fermentations the culture was incubated 
at 37  °C to accumulate the biomass before lowering to 
30  °C prior to induction, but growth at a constant tem-
perature of 30  °C was also tested. 2  mM  MgSO4 was 
added during the fermentation at each increase of ten in 
the  OD600 value. Fed-batch phase started automatically 
when the dissolved oxygen level rose to 40% correspond-
ing to depletion of glucose/glycerol in the media. The 
feeding solution for fed-batch cultivations was based on 
Table 2 Plasmids used in this study
All plasmids except pMJS205 were pET23/Ptac based. pMJS205 is pLysS/Ptac 
based
Plasmid Details Selection References
pMJS144 MH6M‑mature human GH1, 
coErv1p, coPDI
AmpR This study
pMJS145 MH6M‑mature human IL‑6, coErv1p, 
coPDI
AmpR This study
pYU25 MH6M‑mature hen avidin, coErv1p, 
coPDI
AmpR This study
pJV84 scFv human IgA1‑GSH6 Amp
R [16]
pMJS205 coErv1p, coPDI CmR [16]
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fully formulated MSM with the required antibiotics and 
300 g/L glucose/glycerol; the carbon source solution was 
delivered to the bioreactor with exponential feeding rate 
adjusted to specific growth rate µ = 0.15 per hour, which 
is much lower than the maximum growth rate on glu-
cose. Growth at lower specific growth rate helps to avoid 
excretion of acetic acid that is one of major constraints of 
recombinant protein production during aerobic growth 
of E. coli [21, 51].
The exponential feeding profile was calculated accord-
ing to the following equation:
where F(t) is the feeding rate [g/h], μ is the specific 
growth rate  [h−1], V0 is the culture volume [L] and X0 is 
the CDW [g/L] at the end of the batch phase, t is the time 
after feed start [h], S0 [g/g] is the substrate concentration 
in the feeding solution, Yx/s is the yield coefficient [g of 
cell dry weight per g of glucose]:  Yx/s in all calculations 
was 0.4 g/g, m is the maintenance coefficient (0.025 g/g 
[21]).
The cultivation temperature was decreased to 30  °C 
0.6–2  h prior to the induction with 0.1  mM IPTG. 
The cultivations were maintained for about 5  h after 
induction.
For protein analysis samples of the culture were col-
lected from the bioreactor at the end of fermentation; 
samples were centrifuged, the supernatant was discarded 
and the pellets were frozen at −20  °C. For downstream 
processing the pellets were thawed, resuspended in the 
lysis buffer [50 mM sodium phosphate buffer, 0.1 mg/mL 
chicken-egg lysozyme and 40  µg/mL of DNase (Roche), 
pH = 7.4]. Lysis was performed by freeze-thawing.
Cultivations of strains expressing GH1, IL-6 and avi-
din were performed in the Greta multifermentor (Belach 
Bioteknik, Sweden) that allows to operate six 1 L stirred 
tank reactors in parallel. The pH value was adjusted to 
pH = 7.0 by titrating 25% ammonium hydroxide. Oxygen 
level was maintained at 30% of air saturation by cascade 
regulation of stirrer speed (800–1400 rpm) and air flow 
(0.4–2  L/min). Sigma’s Aldrich AntiFoam 204 was used 
to avoid foaming.
Cell growth was followed by measurement of opti-
cal density and cell dry weight. The optical density was 
measured with spectrophotometer (Thermo Electron 
Corporation, Genesys 10 UV) at a wavelength of 600 nm. 
For determination of CDW three 1  mL aliquots of cul-
ture were centrifuged (16,000×g for 3  min at 4  °C) in 
pre-weighed Eppendorf tubes; the supernatant was trans-
ferred to other tube for glucose analysis and the pellets 
were dried at 60 °C for 48 h and the weight was measured 
again.
F(t) =
µV0X0e
µt
S0(YX/S +m)
Glucose concentration in the media was analyzed with 
YSI 2700 Select Biochemical Analyzer (YSI Inc., Yellow 
Springs, USA).
Fermentation cultures expressing scFv  IgA1
Escherichia coli K-12 strain co-transformed with plas-
mids pJV84 and pMJS205 was stored as a 20% glycerol 
stock at −70 °C and was streaked out onto LB-agar plate 
and incubated at 37 °C overnight. The next day a few col-
onies were used to seed 10 mL of LB media and incubated 
overnight (16 h) at 30 °C, 250 rpm. 1 mL of LB pre-cul-
ture was used to inoculate 200 mL of MSM (containing 
30  g/L of glucose), which was then incubated at 30  °C, 
250 rpm, 24 h. The next day the MSM-based culture was 
used to inoculate batch of 0.9 L of MSM media contain-
ing 30 g/L of glucose to a starting OD 600 nm = 0.5.
scFv  IgA1 expressing cultures were grown in Multifors 
system (Infors Ltd, Reigate, UK) that allows to handle 
4 ×  1  L stirred tank reactors in parallel (900  mL work-
ing volume). Appropriate antibiotics were added to the 
defined medium prior to inoculation. 2  mM  MgSO4 
was added during the fermentation at inoculation, 
8  h after induction and 10  h after induction. Ferment-
ers were inoculated with approx. 50  mL cultures to an 
 OD600 =  0.4. During fermentation the dissolved oxygen 
level was maintained at 30% of air saturation by using air 
or air/oxygen mixture as required and by automatic regu-
lation of the stirrer rate (500–1100 rpm). The cultivation 
temperature was maintained at 30 °C. The pH was held at 
7.0, adjusted with 5% v/v solution of ammonium hydrox-
ide. Polypropylene glycol P 2000 was applied to prevent 
foaming.
The process was in the batch mode for 12 h and the fed-
batch started when the biomass concentration reached 
 OD600 around 12 (equivalent to a CDW of about 8 g/L). 
The feeding solution was based on fully formulated MSM 
and contained 650 g/L of glucose. A constant feeding rate 
of 4 mL/h was applied.
The cultures were induced with 1 mM IPTG at an OD 
600 approximately 20 (14 h of cultivation). The cells were 
harvested 18 h post induction.
Fermentation samples were collected from the biore-
actor, centrifuged at 3220×g, the supernatant was dis-
carded, and the pellets were resuspended in the lysis 
buffer [50  mM sodium phosphate buffer, 0.1  mg/mL 
chicken-egg lysozyme and 20  µg/mL of DNase (Roche), 
pH = 7.4], to equivalent of culture  OD600 = 10. Lysis was 
performed by freeze-thawing.
Cell density was monitored by measurements of OD at 
600 nm and samples were taken to determine CDW. For 
determining cell dry weight 1 mL of culture in replicates 
was collected to pre-dried (100 °C, 24 h) and pre-weighed 
1.5  mL Eppendorf tubes; the samples were centrifuged 
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10 min at 16,000×g. Cell pellets were dried at 100 °C for 
24 h and tubes re-weighed.
Concentration of glucose in the fermentation broth was 
monitored on BioProfile FLEX Analyzer (Nova Biomedi-
cal): 1 mL samples of the culture were collected from the 
bioreactor, centrifuged 5 min at 16,000×g and the super-
natants were used for the analysis.
Robustness measurements
Culture samples were collected from bioreactors after 
32 h of cultivation; a rotating disk shear device [52] was 
used to determine the relative robustness of E. coli cells 
[53]. 20 mL of cell broth were exposed for 20 s to a rota-
tion speed of 233 revolutions per second in the device, 
which corresponds to an energy dissipation rate of 
0.75  ×  106  W/kg [52]. This represents the energy nor-
mally generated in high shear producing devices such as 
pumps and process scale centrifuges. Pre and post-shear-
ing samples were centrifuged at 17,000×g for 10  min, 
the supernatants collected and frozen at −20  °C. The 
supernatants were thawed and the total protein content 
in sheared and non-sheared samples was measured via 
Bradford assay (Thermo Scientific, IL, USA) in 96 well 
plate at A 595 nm (Tecan Safire2, Tecan, Reading, UK).
Protein purification
Hexa-histidine tagged proteins were purified via immo-
bilized metal affinity chromatography (IMAC) using 
either prepacked HiTrap IMAC columns (GE Healthcare; 
GH1 or IL-6) or HisPur Cobalt Superflow Agarose Resin 
(Thermo Scientific; GH1, scFv  IgA1 or avidin).
For HiTrap IMAC, a 5  mL column was washed with 
15  mL of water, loaded with 10  mL  NiCl2, washed with 
15 mL water and equilibrated with 2 × 15 mL of 20 mM 
phosphate buffer (pH 7.3). The lysates of the cells were 
thawed at room temperature, centrifuged at 3220×g, 
20 min, 4 °C and the supernatants were loaded onto the 
resin. The resin was then washed with 10 mL of 20 mM 
phosphate buffer (pH 7.3) followed by 20  mL of wash 
buffer (20  mM sodium phosphate, 50  mM imidazole, 
0.3  M sodium chloride; pH 7.3), then 15  mL of 20  mM 
phosphate buffer (pH 7.3). Elution was either with elution 
buffer 1 (20 mM phosphate buffer, 50 mM EDTA; pH 7.3) 
or in parallel samples elution buffer 2 (20 mM phosphate 
buffer, 250 mM imidazole). Circa 1 mL elution fractions 
were collected, analysed by absorbance measurements 
at 280  nm and fractions containing protein pooled. No 
differences were observed in either the yields obtained 
or the purity of the eluted material with the two elution 
methods.
For HisPur Cobalt Superflow Agarose Resin, 1  mL of 
resin was loaded onto the gravity-flow column, washed 
with 2 × 5 mL of water and equilibrated with 2 × 5 mL 
of 50  mM phosphate buffer (pH 7.4). The lysates of the 
cells were thawed at room temperature, centrifuged at 
3220×g, 20 min, 4  °C and the supernatants were loaded 
onto the resin and incubated 5  min. The resin was 
equilibrated with 5 mL of 50 mM phosphate buffer (pH 
7.4) and washed with 4 × 5 mL of wash buffer (50 mM 
sodium phosphate, 15  mM imidazole, 0.3  M sodium 
chloride; pH 7.4), equilibrated again with 5 mL of 50 mM 
sodium phosphate (pH 7.4) before elution with 4 × 1 mL 
of elution buffer (50 mM phosphate buffer, 50 mM EDTA 
buffer; pH 7.4).
After IMAC the purified protein samples were desalted 
on PD-10 columns (GE Healthcare) according to the 
manufacturer’s instructions into either 20 mM phosphate 
buffer pH 7.3 or 50  mM phosphate buffer pH 7.4. The 
protein concentration was determined via absorbance 
measurements at 280  nm. Total cell lysate, soluble pro-
tein fraction and purified protein samples were analyzed 
on reducing SDS-PAGE stained with Coomassie brilliant 
blue.
Protein analysis
Ellman’s assay for free thiol content was performed 
under denaturing conditions: the purified protein sample 
was mixed with 50 mM Tris buffer (pH 8.0), 6 M guani-
dine hydrochloride to a final concentration of 2  M and 
0.073 mg/mL of Ellman’s reagent; the samples were incu-
bated at room temperature for 15  min and the absorb-
ance was monitored at 412 nm compared to a no protein 
control sample. The free thiol content was calculated 
using a molar extinction coefficient of 13,600 M−1 cm−1.
Reverse phase high pressure liquid chromatography 
(rpHPLC) analysis was performed on an ÄKTA FPLC sys-
tem (GE Healthcare) using a μRPC C2/C18 ST 4.6/100 col-
umn: The column was pre-equilibrated in buffer A (0.065% 
trifluoroacetic acid), before a 50 μL sample was loaded to 
the system using automatic sample injection. The elution 
gradient used was 0-100% buffer B (90% acetonitrile, 0.05% 
trifluoroacetic acid) over 8 column volumes. 0.5 mL frac-
tions were collected with a flow rate of 0.3  mL/min. All 
buffers were filtered and degassed before use.
Molecular masses were measured by LCMS with an 
Aquity UPLC-system (Waters) connected to a Synapt G1 
Q-ToF—type mass spectrometer. The analytical column 
was a BEH 300 C4, 2.1 × 100 mm (Waters) run at 0.4 mL/
min using a gradient from 3% acetonitrile in water/0.1% 
formic acid to 43% acetonitrile over 1 min. Samples were 
acidified with trifluoroacetic acid to about 0.5% v/v and 
5 µL was injected. The mass spectrometer was operated 
in sensitivity mode with lock mass corrected 1 s scans in 
continuous mode for m/z 100–2000. Capillary voltage 
was 3.5  kV, cone voltage 30  V. Baseline was subtracted 
and mass spectra were deconvoluted with MaxEnt1.
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